Revolution Medicines (RVMD) Total Liabilities (2019 - 2026)

Revolution Medicines has reported Total Liabilities for 8 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 204.33% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 204.33% increase from a year earlier, with the FY2025 full-year figure at $723.2 million, up 146.75% from the prior year.
• Total Liabilities was $1.7 billion for Q2 2026 at Revolution Medicines, up from $753.8 million in the prior quarter.
• The five-year high for Total Liabilities was $1.7 billion in Q2 2026, with the low at $121.0 million in Q1 2023.
• Average Total Liabilities over 5 years is $374.8 million, with a median of $193.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities dropped 8.16% in 2023, then jumped 233.01% in 2025.
• Over 5 years, Total Liabilities stood at $126.7 million in 2022, then surged by 85.82% to $235.5 million in 2023, then advanced by 24.45% to $293.1 million in 2024, then surged by 146.75% to $723.2 million in 2025, then soared by 137.42% to $1.7 billion in 2026.
• The last three Total Liabilities figures came in at $1.7 billion (Q2 2026), $753.8 million (Q1 2026), and $723.2 million (Q4 2025), per Business Quant data.